These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 39400342)

  • 1. The New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity-Matched Comparison With Standard Perioperative Therapy.
    Rencuzogullari A; Karahan SN; Selcukbiricik F; Lacin S; Taskin OC; Saka B; Karahacioglu D; Gurses B; Ozoran E; Uymaz DS; Ozata IH; Saglam S; Bugra D; Balik E
    J Surg Oncol; 2024 Oct; ():. PubMed ID: 39400342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
    Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
    Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
    Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
    BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective.
    Sisic L; Crnovrsanin N; Nienhueser H; Jung JO; Schiefer S; Haag GM; Bruckner T; Schneider M; Müller-Stich BP; Büchler MW; Schmidt T
    Langenbecks Arch Surg; 2023 Feb; 408(1):81. PubMed ID: 36763220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
    Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
    BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy.
    Paszt A; Simonka Z; Budai K; Horvath Z; Erdos M; Vas M; Ottlakan A; Nyari T; Szepes Z; Uhercsak G; Maraz A; Torday L; Tiszlavicz L; Olah J; Lazar G
    Front Surg; 2023; 10():1148984. PubMed ID: 37077865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer.
    Zhang Y; Zhang B; Yang J; Zhang J; Zhang W
    Cancer Manag Res; 2021; 13():2279-2286. PubMed ID: 33732020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study.
    Li N; Li Z; Fu Q; Zhang B; Zhang J; Wan XB; Lu CM; Wang JB; Deng WY; Ma YJ; Bie LY; Wang MY; Li J; Xia QX; Wei C; Luo SX
    Int J Surg; 2024 Apr; 110(4):2071-2084. PubMed ID: 38320099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Short term results of the FLOT neoadjuvant therapy on the surgical management of advanced gastro-oesophageal junction adenocarcinoma].
    Paszt A; Simonka Z; Budai K; Erdős M; Vas M; Ottlakán A; Szepes Z; Torday L; Tiszlavicz L; Lázár G
    Magy Seb; 2022 Jun; 75(2):142-150. PubMed ID: 35895528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
    Lorenzen S; Pauligk C; Homann N; Schmalenberg H; Jäger E; Al-Batran SE
    Br J Cancer; 2013 Feb; 108(3):519-26. PubMed ID: 23322206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
    Shitara K; Rha SY; Wyrwicz LS; Oshima T; Karaseva N; Osipov M; Yasui H; Yabusaki H; Afanasyev S; Park YK; Al-Batran SE; Yoshikawa T; Yanez P; Dib Bartolomeo M; Lonardi S; Tabernero J; Van Cutsem E; Janjigian YY; Oh DY; Xu J; Fang X; Shih CS; Bhagia P; Bang YJ;
    Lancet Oncol; 2024 Feb; 25(2):212-224. PubMed ID: 38134948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 14. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial.
    Reynolds JV; Preston SR; O'Neill B; Lowery MA; Baeksgaard L; Crosby T; Cunningham M; Cuffe S; Griffiths GO; Parker I; Risumlund SL; Roy R; Falk S; Hanna GB; Bartlett FR; Alvarez-Iglesias A; Achiam MP; Nilsson M; Piessen G; Ravi N; O'Toole D; Johnston C; McDermott RS; Turkington RC; Wahed S; Sothi S; Ford H; Wadley MS; Power D;
    Lancet Gastroenterol Hepatol; 2023 Nov; 8(11):1015-1027. PubMed ID: 37734399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT.
    Geerts JFM; van der Zijden CJ; van der Sluis PC; Spaander MCW; Nieuwenhuijzen GAP; Rosman C; van Laarhoven HWM; Verhoeven RHA; Wijnhoven BPL; Lagarde SM; Mostert B
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610969
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
    Moussa O; Bhogal RH; Malietzis G; Fribbens C; Starling N; Gerlinger M; Watkins D; Chau I; Rao S; Cunningham D; Allum WH; Chaudry A; Kumar S
    BJS Open; 2022 Jan; 6(1):. PubMed ID: 35195263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO.
    Götze TO; Piso P; Lorenzen S; Bankstahl US; Pauligk C; Elshafei M; Amato G; Reim D; Bechstein WO; Königsrainer A; Mönig SP; Rau B; Schwarzbach M; Al-Batran SE
    BMC Cancer; 2021 Oct; 21(1):1158. PubMed ID: 34715810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLOT Neoadjuvant Chemotherapy Followed by Laparoscopic D2 Gastrectomy in the Treatment of Locally Resectable Advanced Gastric Cancer.
    Zhang S; Yan D; Sun Q; Du T; Cao D; Yang Y; Yuan B; Li H; Jiang X; Song C
    Can J Gastroenterol Hepatol; 2020; 2020():1702823. PubMed ID: 32566545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    Al-Batran SE; Homann N; Pauligk C; Illerhaus G; Martens UM; Stoehlmacher J; Schmalenberg H; Luley KB; Prasnikar N; Egger M; Probst S; Messmann H; Moehler M; Fischbach W; Hartmann JT; Mayer F; Höffkes HG; Koenigsmann M; Arnold D; Kraus TW; Grimm K; Berkhoff S; Post S; Jäger E; Bechstein W; Ronellenfitsch U; Mönig S; Hofheinz RD
    JAMA Oncol; 2017 Sep; 3(9):1237-1244. PubMed ID: 28448662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) as preoperative and postoperative chemotherapy compared with surgery followed by chemotherapy for patients with locally advanced gastric cancer: a propensity score-based analysis.
    Wang K; Ren Y; Ma Z; Li F; Cheng X; Xiao J; Zhang S; Yu Z; Yang H; Zhou H; Li Y; Liu H; Jiao ZY
    Cancer Manag Res; 2019; 11():3009-3020. PubMed ID: 31114348
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.